Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark
Elisabeth Framke(Copenhagen University Hospital), Melinda Magyari(University of Copenhagen), Finn Sellebjerg(Kaiser Permanente), Morten Schou(British Heart Foundation), Lau Caspar Thygesen(University of Southern Denmark), Morten Malmborg(Gentofte Hospital)
Cited by 10
Related Papers
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2024|693
Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial
|European Journal of Heart Failure|2016|561
Worldwide Incidence and Prevalence of Neuromyelitis Optica
|Neurology|2020|303